Please assess the completion status of the following clinical trial:

Trial Title: Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women ≥18 years of age.~* Confirmed diagnosis of MBC (stage IV).~* Breast adenocarcinoma confirmed histologically.~* HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.~* Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.~* Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).~Exclusion Criteria:~* Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.~* Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.~* Patients who have taken part in any clinical trial (interventional) during the study period.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane® treatment in patients with metastatic breast cancer (Type: None): Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).